Use of Caval Subtraction 2D Phase-Contrast MR Imaging to Measure Total Liver and Hepatic Arterial Blood Flow: Preclinical Validation and Initial Clinical Translation by Chouhan, MD et al.
Original research n
 Technical Developm
enT
Radiology: Volume 000: Number 0—   2016 n radiology.rsna.org 1
1 From the University College London Centre for Medical 
Imaging (M.D.C., S.H., S.A.T.), Institute for Liver and 
Digestive Health (R.P.M., N.D.), and Centre for Advanced 
Biomedical Imaging (S.W.S., M.F.L.), Division of Medicine, 
University College London, 250 Euston Rd, 3rd Floor East, 
London NW1 2PG, England; and Department of Medical 
Physics, University College London Hospitals NHS Trust, 
London, England (A.B.). Received August 7, 2015; revision 
requested October 15; revision received November 17; 
accepted December 23; final version accepted January 
13, 2016. Address correspondence to S.A.T. (e-mail: 
csytaylor@yahoo.co.uk).
The study was supported by the National Institute for 
Health Research, University College London Hospitals 
Biomedical Research Centre. S.H. and S.A.T. are senior 
investigators for the National Institute for Health Research, 
and M.D.C. is a clinical lecturer for the National Institute for 
Health Research. M.D.C. was supported by the Wellcome 
Trust (grant WT092186).
Published under a CC BY 4.0 license.
Purpose: To validate caval subtraction two-dimensional (2D) phase-
contrast magnetic resonance (MR) imaging measurements of 
total liver blood flow (TLBF) and hepatic arterial fraction in 
an animal model and evaluate consistency and reproducibility 
in humans.
Materials and 
Methods:
Approval from the institutional ethical committee for animal 
care and research ethics was obtained. Fifteen Sprague-Daw-
ley rats underwent 2D phase-contrast MR imaging of the por-
tal vein (PV) and infrahepatic and suprahepatic inferior vena 
cava (IVC). TLBF and hepatic arterial flow were estimated 
by subtracting infrahepatic from suprahepatic IVC flow and 
PV flow from estimated TLBF, respectively. Direct PV transit-
time ultrasonography (US) and fluorescent microsphere mea-
surements of hepatic arterial fraction were the standards of 
reference. Thereafter, consistency of caval subtraction phase-
contrast MR imaging–derived TLBF and hepatic arterial flow 
was assessed in 13 volunteers (mean age, 28.3 years 6 1.4) 
against directly measured phase-contrast MR imaging PV and 
proper hepatic arterial inflow; reproducibility was measured 
after 7 days. Bland-Altman analysis of agreement and coeffi-
cient of variation comparisons were undertaken.
Results: There was good agreement between PV flow measured with 
phase-contrast MR imaging and that measured with transit-
time US (mean difference, 23.5 mL/min/100 g; 95% limits 
of agreement [LOA], 661.3 mL/min/100 g). Hepatic arterial 
fraction obtained with caval subtraction agreed well with those 
with fluorescent microspheres (mean difference, 4.2%; 95% 
LOA, 620.5%). Good consistency was demonstrated between 
TLBF in humans measured with caval subtraction and direct 
inflow phase-contrast MR imaging (mean difference, 21.3 mL/
min/100 g; 95% LOA, 623.1 mL/min/100 g). TLBF reproduc-
ibility at 7 days was similar between the two methods (95% 
LOA, 631.6 mL/min/100 g vs 629.6 mL/min/100 g).
Conclusion: Caval subtraction phase-contrast MR imaging is a simple and 
clinically viable method for measuring TLBF and hepatic ar-
terial flow.
Published under a CC BY 4.0 license.
Online supplemental material is available for this article.
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infrahepatic, suprarenal portion of the 
IVC (Qinfrahepatic) (Fig E1a [online]), as 
follows:
QTLBF = Qsuprahepatic 2 Qinfrahepatic. (2)
Hepatic arterial flow (QHA) can then be 
estimated by subtracting directly mea-
sured PV flow (QPV) from the outflow 
TLBF (Fig E1b [online], as follows:
 QHA = QTLBF 2 QPV. (3)
Preclinical Validation
Subjects and preparation.—All exper-
iments were conducted according to 
the home office guidelines under the 
U.K. Animals in Scientific Procedures 
Act (1986) after approval from the An-
imal Care Ethical Committee of Uni-
versity College London. Experiments 
were performed between September 
12 and October 17, 2013, on healthy 
male Sprague-Dawley rats (Charles 
River UK, Margate, England) with nor-
mal liver function (weight, 250–300 g).
The study cohort consisted of 15 
healthy animals treated with sham lap-
arotomy (n = 11) or bile duct ligation 
(BDL) (n = 4). The latter group was in-
cluded to test the feasibility of perform-
ing phase-contrast MR imaging in an 
imaging is an established, widely avail-
able, and validated method for the 
noninvasive measurement of large-
vessel bulk flow (2–5). Several inves-
tigators have used phase-contrast MR 
imaging to study PV flow, although few 
have reported data from the proper 
hepatic artery (6–9) because evalua-
tion is challenging in routine clinical 
practice, primarily because of small 
vessel size, tortuosity, and anatomic 
variation. Furthermore, low signal-
to-noise ratio, vessel orthogonality, 
partial volume averaging errors, in-
travoxel phase dispersion, and spatial 
misregistration can confound estima-
tion of pulsatile flow in small arteries 
and have impeded both research and 
clinical use of phase-contrast MR im-
aging for the measurement of total 
liver blood flow (TLBF).
Recognizing these challenges, we 
propose an alternative application of 2D 
phase-contrast MR imaging to measure 
TLBF and proper hepatic arterial flow 
by using caval subtraction. TLBF and 
hepatic arterial flow fraction could be 
valuable hemodynamic biomarkers of 
liver disease. The purpose of this study 
was to validate caval subtraction 2D 
phase-contrast MR imaging measure-
ments of TLBF and hepatic arterial 
fraction in a preclinical animal model 
and evaluate consistency and reproduc-
ibility in humans.
Materials and Methods
Background Theory
From the application of the principle of 
conservation of mass to flow (Q), for a 
fixed tissue volume:
 Qin = Qout, (1)
where Qin is blood flow into the organ 
and Qout is blood flow out of the organ. 
On the basis of the anatomic configura-
tion of the liver, the intrahepatic infe-
rior vena cava (IVC) receives blood en-
tirely from the hepatic venous system. 
Outflow TLBF (Qout, equivalent to QTLBF) 
can therefore be estimated by measur-
ing bulk flow in the suprahepatic sub-
cardiac portion of the IVC (Qsuprahepatic) 
and then subtracting flow from the 
Published online before print
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Advances in Knowledge
 n In a rodent model, portal venous 
flow measurement obtained with 
two-dimensional (2D) phase-con-
trast MR imaging demonstrates 
good agreement with invasive 
transit-time US (mean difference, 
23.5 mL/min/100 g; Bland-Alt-
man 95% limits of agreement 
[LOA], 661.3 mL/min/100 g).
 n In a rodent model, hepatic arte-
rial fraction measurement 
obtained with caval subtraction 
2D phase-contrast MR imaging 
demonstrates good agreement 
with an invasive microsphere 
standard of reference (mean 
difference, 4.2%; 95% LOA, 
620.5%).
 n In human volunteers, total liver 
blood flow (TLBF) estimated 
with caval subtraction 2D phase-
contrast MR imaging shows good 
agreement with that calculated 
from direct inflow phase-contrast 
MR imaging (mean difference, 
21.3 mL/min/100 g; 95% LOA, 
623.1 mL/min/100 g).
 n In human volunteers, caval sub-
traction TLBF and directly mea-
sured inflow phase-contrast MR 
imaging TLBF at 7 days were 
similar (95% LOA, 631.6 mL/
min/100 g vs 629.6 mL/min/ 
100 g).
 n Caval subtraction 2D phase-con-
trast MR imaging is a noninva-
sive, simple, and rapid technique 
for measuring total liver and he-
patic arterial blood flow.
The dual portal venous (PV) and hepatic arterial blood supply to the liver makes it difficult to as-
sess hemodynamic complications of 
liver disease. To date, invasive methods 
still remain the standard of reference. 
Imaging-based hepatic hemodynamic 
assessment has the potential to yield 
useful and meaningful biomarkers of 
portal hypertension and chronic liver 
disease (1).
Two-dimensional (2D) phase-
contrast magnetic resonance (MR) 
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basis of established algorithms (12). All 
PV flow, estimated TLBF, and hepatic 
arterial flow measurements were nor-
malized to explanted liver weight.
Human Translation
Two aspects of the caval subtraction 
technique were then tested in healthy 
volunteers: (a) consistency with directly 
measured phase-contrast MR imaging PV 
and hepatic arterial inflow and (b) mea-
surement reproducibility after 7 days.
Subjects and preparation.—Univer-
sity College London Ethics Committee 
approval was obtained, and participants 
provided informed written consent. 
Volunteers were recruited by means 
of advertisement within the university 
campus and were eligible if they (a) had 
no contraindications to MR imaging, (b) 
were not taking any long-term medica-
tion (excluding the oral contraceptive 
pill), and (c) had no documented his-
tory of previous liver or gastrointesti-
nal disease. Fourteen volunteers were 
screened, one of whom was excluded 
because of claustrophobia. The final 
cohort consisted of seven men (mean 
age 6 standard deviation, 26.5 years 6 
1.36) and six women (mean age, 31.2 
years 6 2.62) who underwent imaging 
between June 14 and July 25, 2013. Par-
ticipants fasted for 6 hours before MR 
imaging and avoided caffeinated fluids.
were used to identify the IVC and PV, 
and phase-contrast image planes were 
planned to ensure orthogonality with 
the subcardiac portion of the suprahe-
patic IVC, suprarenal portion of the in-
frahepatic IVC, and PV.
Cardiac- and respiratory-gated 2D 
cine phase-contrast MR imaging was 
performed with 2-mm-thick sections, 
a 10° flip angle, and a 192 3 192 
(frequency encoding 3 phase encod-
ing) acquisition matrix. On the basis of 
initial pilot work in four animals (not 
presented in this study), velocity encod-
ing (Venc) settings of 33 cm/sec for PV 
and infrahepatic IVC flows and 66 cm/
sec for suprahepatic IVC flows were 
applied (Table). Phase maps were ac-
quired at each Venc setting with oppo-
site flow-encoding directions. Correc-
tion for background phase errors was 
achieved by subtracting phase maps 
with opposing flow-encoding directions, 
with the assumption that the phase of 
stationary spins was identical in each 
image. Acquisition time for each phase-
contrast MR imaging measurement was 
usually less than 10 minutes. Regions of 
interest were positioned manually by 
the study coordinator on each vessel 
for each frame of the cardiac cycle, and 
flow quantification was performed by 
using in-house-developed Matlab code 
(MathWorks, Natick, Mass) on the 
animal model of portal hypertension. 
BDL and sham surgery were conduct-
ed as described previously (10). After 
recovery, animals were maintained for 
4–5 weeks before undergoing the ex-
perimental protocol. All procedures 
were performed by the study coordina-
tor (M.D.C., a radiology research fel-
low qualified in animal handling with 4 
years of experience).
Standards of reference.—For rats 
that underwent sham operation (n = 
11), laparotomy was performed and 
a 2-mm transit-time US probe (Tran-
sonic Systems, Ithaca, NY) was placed 
around the PV. PV flow readings were 
obtained with transit-time US after 
10–15 minutes, once the animal was 
stable. Extensive adhesions around the 
porta hepatis and associated high risk 
of traumatic vessel injury precluded 
transit-time US validation in the BDL 
group.
After transit-time US measure-
ment, 15-mm polystyrene fluorescent 
microspheres (FluoSpheres; Life Tech-
nologies, Warrington, England) sus-
pended in heparinized saline were ad-
ministered transcutaneously into the 
left ventricle over approximately 10 
seconds under US guidance (Terason; 
Teratech, Burlington, Mass) (Fig E2 
[online]). Animals were then trans-
ferred to the imager for phase-contrast 
MR imaging. The animal was then 
sacrificed and organs were explanted 
for microsphere processing using an 
adapted protocol (11), as summarized 
in Appendix E1 (online). To ensure ad-
equate central mixing of microspheres, 
data exceeding 20% difference in mi-
crosphere content between right and 
left kidneys were excluded.
Two-dimensional cine phase-con-
trast MR imaging.—Temperature was 
monitored with a rectal probe (SA In-
struments, New York, NY), with core 
body temperature maintained between 
36°C and 38°C. Cardiac monitoring 
was undertaken by using a triple-elec-
trode single-lead system (SA Instru-
ments). Imaging was performed by us-
ing a 9.4-T unit (Agilent Technologies, 
Oxford, England), with sequence pa-
rameters listed in the Table. Axial and 
angled coronal gradient-echo images 
Sequence Parameters
Parameter
Preclinical Examination (9.4 T) Clinical Examination (3.0 T)
Anatomic Imaging* 
Phase-Contrast  
MR Imaging† Anatomic Imaging‡ 
Phase-Contrast  
MR Imaging† 
TR/TE (msec) 8.2/5.6 10/1.2 2.47/1.23 8.70/5.22
Flip angle (degrees) 20 10 45 10
Matrix size (pixels) 128 3 128 192 3 192 352 3 352 336 3 336
Field of view (mm) 80 3 80 40 3 40 350 3 350 271 3 210
Spatial resolution (mm2) 0.625 3 0.625 0.208 3 0.208 0.994 3 0.994 0.808 3 0.625
Section thickness (mm) 2 2 5 5
Section gap (mm) 4.5 … 5.5 …
Cardiac cycle phases … 12–15 … 7
Note.—TR/TE = repetition time/echo time.
* Performed with a gradient-echo sequence.
† Performed with a gradient-echo sequence with additional bipolar phase contrast gradients.
‡ Performed with steady-state free precession.
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in the BDL group had evidence of cir-
rhosis at histopathologic examination.
Technical feasibility of caval sub-
traction phase-contrast MR imag-
ing.—Electrocardiographically and 
respiratory-gated cine phase-contrast 
MR imaging flow studies through the 
cardiac cycle demonstrated physiologic 
flow profiles through the PV and infra-
hepatic and suprahepatic IVC (Fig E3 
[online]).
Validation of PV and relative he-
patic arterial flow.—Comparing phase- 
contrast MR imaging versus transit-
time US (n = 11), the mean difference 
between PV flow directly measured with 
phase-contrast MR imaging (mean, 
182.8 mL/min/100 g 6 9.9) and transit-
time US (mean, 186.3 mL/min/100 g 6 
11.9) was 23.5 mL/min/100 g 6 9.4, 
with 95% LOA of 661.3 mL/min/100 g 
(Fig 1a). The coefficient of variation for 
PV flow was similar for transit-time US 
(21.2%) compared with phase-contrast 
MR imaging (17.9%) (F10,10 = 1.38, 
P = .31).
In the comparison of phase-con-
trast MR imaging with microspheres, 
seven animals had inadequate cen-
tral mixing of microspheres and were 
excluded, leaving eight for analysis 
(sham, n = 4; BDL, n = 4). The mean 
difference between relative hepatic 
arterial flow derived from phase-con-
trast MR imaging with caval subtrac-
tion (Eq [3]; mean, 35.3% 6 11.6) 
and that calculated from the micro-
sphere distribution analysis (mean, 
31.1% 6 9.8) was 4.2% 6 3.7, with 
95% LOA of 620.5% (Fig 1c). The 
coefficient of variation was similar for 
caval subtraction phase-contrast MR 
imaging (93.0%) and microsphere 
analysis (89.2%) (F7,7 = 0.95, P = 
.52). Relative hepatic arterial flow was 
greater and PV flow was lower in ani-
mals with cirrhosis and portal hyper-
tension (relative hepatic arterial flow: 
50.3% 6 13.5 in BDL group vs 11.8% 
6 4.3 in sham group; PV flow: 94.3 
mL/min/100 g 6 28.8 in BDL group vs 
167.0 mL/min/100 g 6 20.3 in sham 
group), but these differences were 
not statistically significant (hepatic 
arterial fraction, P = .0571; PV flow, 
P = .200).
(Eqq [2, 3]) and compared with direct 
phase-contrast MR imaging of PV and 
hepatic arterial inflow.
Liver volume was estimated by us-
ing steady-state free precession coronal 
images with 5-mm-thick sections. Seg-
mentation was performed manually by 
the study coordinator using software 
(Amira Resolve RT; Visage Imaging, 
Berlin, Germany). A tissue density of 
1.0 g/mL was assumed (13).
Seven days after the original study, 
subjects underwent repeat imaging 
with identical preparation and MR im-
aging protocol at a comparable time of 
the day. All analyses and quantification 
were performed by the study coordina-
tor (M.D.C., with 5 years of experience 
in abdominal imaging).
Statistical Analysis
Data normality was confirmed with 
Kolmogorov-Smirnov testing. All bulk 
flow measurements obtained at phase-
contrast MR imaging were normalized 
to liver weight or volume. Comparison 
between measurements derived from 
caval subtraction phase-contrast MR 
imaging and standards of reference 
(transit-time US, microspheres, direct 
inflow phase-contrast MR imaging) and 
7-day reproducibility studies were as-
sessed by using Bland-Altman analysis 
of agreement, with calculation of 95% 
limits of agreement (LOA). Coefficients 
of variation were also calculated and 
compared by using methods described 
by Forkman (14). Because of the small 
number of animals in the sham and 
BDL groups that underwent validation 
with microsphere analysis, validation 
analysis was pooled across both cohorts 
and the Mann-Whitney U test used for 
comparison of PV and relative hepatic 
arterial flow. Data are expressed as 
means 6 standard errors, and P , .05 
was indicative of a statistically significant 
difference.
Results
Preclinical Cohort
Across 15 animals, the mean body 
weight was 451.7 g 6 9.0 and the wet 
liver mass was 24.7 g 6 2.0. All animals 
Two-dimensional cine phase-con-
trast MR imaging.—Phase-contrast MR 
imaging was performed with a 3.0-T 
unit (Achieva; Philips Healthcare, Best, 
the Netherlands) and a 16-channel 
body coil (SENSE XL-Torso, Philips 
Healthcare). Imaging parameters are 
given in the Table.
Coronal (upper abdomen), sagittal 
(abdominal great vessels), and oblique 
(PV) breath-hold balanced steady-
state free precession images were 
acquired. Two-dimensional phase-
contrast MR imaging with expiratory 
breath hold and retrospective cardiac 
gating was planned in two planes by 
the study coordinator to ensure or-
thogonality to the target vessel. Stud-
ies were performed through the PV 
(Venc = 40 cm/sec), proper hepatic 
artery (Venc = 60 cm/sec), infrahepatic 
IVC (above the renal veins, below the 
hepatic IVC; Venc = 60 cm/sec), and 
suprahepatic IVC (above the hepatic 
venous inflow, below the right atrial 
junction; Venc = 80 cm/sec). Where 
hepatic arterial anatomy varied (n 
= 2), measurements were made as 
close as possible to the origin of the 
hepatic artery. Images were reviewed 
for aliasing and Venc settings increased 
by 20 cm/sec when appropriate. Data 
were acquired by using the unit’s clin-
ical flow quantification implementa-
tion. Phase maps were acquired at 
each Venc setting with opposite flow-
encoding directions. Correction for 
background phase errors was achieved 
by subtracting phase maps with op-
posing flow-encoding directions, with 
the assumption that the phase of sta-
tionary spins was identical in each 
image. A local phase-correction filter 
was also applied to correct for phase 
errors induced by eddy currents. The 
acquisition time for each measure-
ment was less than 20 seconds. Each 
phase-contrast MR imaging study was 
repeated three times. Flow quantifi-
cation was performed by using freely 
available software (Segment; Med-
viso, Lund, Sweden) and the mean 
of triplicate measurements used for 
analysis. Caval subtraction TLBF, PV 
flow, hepatic arterial flow, and he-
patic arterial fraction were calculated 
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min/100 g, respectively) (Fig 2a, 2c). The 
coefficient of variation for caval subtrac-
tion phase-contrast MR imaging TLBF 
(23.0%) was similar to that for direct 
inflow TLBF (22.2%) (F23,23 = 0.94, P 
= .56). Hepatic arterial flow with caval 
subtraction phase-contrast MR imaging 
(123.2%) was higher than that with di-
rect phase-contrast MR imaging (75.6%), 
although this did not reach statistical sig-
nificance (F23,23 = 1.68, P = .11).
Seven-day reproducibility.—The 
mean differences between TLBF mea-
sured with caval subtraction phase-
contrast MR imaging and hepatic arte-
rial flow measurements obtained 7 days 
apart were 28.5 mL/min/100 g 6 4.9 
TLBF measured with caval subtraction 
phase-contrast MR imaging (mean, 71.1 
mL/min/100 g 6 3.3) and that measured 
with direct phase-contrast MR imaging 
(sum of PV and common hepatic arterial 
flow; mean, 72.5 mL/min/100 g 6 3.3) 
and between calculated hepatic arterial 
flow (Eq [3]; mean, 14.0 mL/min/100 
g 6 3.5) and direct phase-contrast MR 
imaging measured hepatic arterial flow 
(mean, 15.3 mL/min/100 g 6 2.4) was 
21.3 mL/min/100 g 6 2.4. The 95% 
LOA for caval subtraction versus direct 
inflow phase-contrast MR imaging were 
623.1 mL/min/100 g for both TLBF and 
hepatic arterial flow (range, 40.5–100.9 
mL/min/100 g and 220.7 to 54.9 mL/
Clinical Cohort
The mean liver volume was 1211.0 mL 
6 52.9. Two subjects declined subse-
quent examination, leaving 11 in the re-
producibility cohort.
Technical feasibility of caval sub-
traction phase-contrast MR imag-
ing.—Electrocardiographically and 
respiratory-gated cine phase-contrast 
MR imaging flow studies through the 
cardiac cycle demonstrated physiologic 
flow profiles through the PV, infrahe-
patic IVC, and suprahepatic IVC (Fig 
E4 [online]).
Caval subtraction phase-contrast MR 
imaging versus direct phase-contrast MR 
imaging.—The mean difference between 
Figure 1
Figure 1: Validation of phase-contrast MR imaging PV flow and caval subtraction phase-contrast MR imaging–derived hepatic arterial (HA) fraction in sham-
operated () and BDL () rats. (a, c) Bland-Altman plots and (b, d) scatterplots show agreement between (a, b) PV flow at phase-contrast MR imaging and 
transit-time US (TTUS) and (c, d) hepatic arterial fraction at caval subtraction phase-contrast MR imaging and fluorescent microspheres.
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voluming and spatial resolution remain 
problematic, particularly at 1.5 T (7). 
Furthermore, frequent anatomic varia-
tion (18–20) complicates measurement 
and requires costly radiologic expertise 
for planning, which substantially im-
pedes clinical implementation.
We have demonstrated that caval 
subtraction phase-contrast MR imaging 
provides a relatively simple strategy for 
overcoming these limitations in both 
rodents and humans. We found that 
phase-contrast MR imaging is techni-
cally feasible in animals (even in a cir-
rhotic BDL model), and phase-contrast 
MR imaging PV flow estimates showed 
Discussion
Accurate assessment of proper hepatic 
arterial flow (and, consequently, TLBF) 
with use of phase-contrast MR imaging 
is challenging in both preclinical and 
clinical contexts. In rodents, the vessel 
itself is extremely small—less than 1 
mm in diameter (15–17)—which intro-
duces measurement errors, even at high 
field strengths. Technical challenges 
have confounded attempts to measure 
proper hepatic arterial flow in humans 
with clinical systems (6–9). Adequate 
signal-to-noise ratio is less of an issue 
because the vessel is larger, but partial 
and 7.3 mL/min/100 g 6 4.4, respec-
tively. The 95% LOA were 631.6 mL/
min/100 g for TLBF and 628.8 mL/
min/100 g for hepatic arterial flow. The 
mean difference between directly mea-
sured phase-contrast MR imaging TLBF 
and hepatic arterial flow measurements 
obtained 7 days apart were 22.3 mL/
min/100 g 6 4.5 and 1.1 mL/min/100 g 
6 3.0, respectively. The caval subtrac-
tion 95% LOA were 631.6 mL/min/100 
g for TLBF and 628.8 mL/min/100 g 
for hepatic arterial flow. The 95% LOA 
were 629.6 mL/min/100 g for TLBF and 
619.5 mL/min/100 g (range, 4.9–44.6 
mL/min/100 g) for hepatic arterial flow.
Figure 2
Figure 2: Consistency of caval subtraction phase-contrast MR imaging. Caval subtraction phase-contrast MR imaging TLBF and hepatic arterial flow in healthy 
volunteers were compared with contemporaneous inflow phase-contrast MR imaging measurements. Data were pooled from baseline and 7-day reproducibility 
studies. (a, c) Bland-Altman plots and (b, d) scatterplots show agreement between (a, b) TLBF estimated at caval subtraction imaging and that determined at inflow 
phase-contrast MR imaging and between (c, d) hepatic arterial flow estimated at caval subtraction imaging and proper hepatic arterial flow at inflow phase-contrast 
MR imaging.
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parameters for determining both man-
agement and prognosis (27), the value 
of absolute flow parameters in clinical 
practice remains unclear. Caval sub-
traction phase-contrast MR imaging 
may also have limitations in the assess-
ment of some patients with chronic liver 
disease: The presence of large extrahe-
patic portosystemic shunts (eg, recana-
lized umbilical vein or gastric varices), 
retrograde PV flow, or venous outflow 
obstruction (Budd-Chiari syndrome) 
are likely to compromise simple caval 
subtraction assessment of TLBF or he-
patic arterial flow. In addition, gating 
to a specific phase of respiration can 
potentially introduce (systematic) er-
rors, particularly if caval blood flow at 
different levels is variably influenced by 
respiration phase, a phenomenon that 
was not investigated in this study. Fi-
nally, studies in anesthetized animals 
and healthy volunteers represent ideal 
conditions to test the technique given 
the compliance with imaging protocols. 
Studies translating this method into po-
tentially less compliant, unwell patients 
with chronic liver disease are planned 
and are necessary to determine the 
value of caval subtraction phase-con-
trast MR imaging in clinical practice.
Caval subtraction phase-contrast 
MR imaging is a simple and rapid tech-
nique, amenable to technologist-led 
phase-contrast MR imaging planning 
in clinical practice. It could also be 
used for noninvasive validation of more 
complex methods such as four-dimen-
sional phase-contrast MR imaging. In 
summary, we have demonstrated that 
caval subtraction phase-contrast MR 
imaging is technically feasible and may 
offer a reproducible and clinically vi-
able method for measuring TLBF and 
hepatic arterial flow.
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